[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Keri Medical SA\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":64},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100624157","touch-cmc-1-new-enrollment-us-study-100624157",false,"NCT07405983","TOUCH® CMC 1 New Enrollment US Study","Effectiveness and Safety of the TOUCH® CMC 1 Prosthesis, Post-Approval Study","PAS002","Inclusion Criteria:\n\n1. Patient requiring 1st carpometacarpal (CMC) primary total joint replacement (arthroplasty) to surgically treat symptomatic Eaton-Littler Stage II or III osteoarthritis (OA)\n2. Adult (≥ 22 years of age) at the time of enrollment\n3. Willing and able to sign the study Informed Consent\n\nExclusion Criteria:\n\n1. Acute or chronic infections, local or systemic\n2. Muscular, neurological, or vascular severe deficiency affecting the joint\n3. Inadequate bone quality or quantity preventing the implant fixation\n4. Bones dimensions incompatible with implant sizes\n5. Patients who are allergic to the product's materials\n6. Any concomitant disorder that may affect the function of the implant (e.g., osteoarthritis of the wrist)\n7. Skeletally immature (i.e., pediatric population, \\\u003C22 years of age)\n8. Pregnant or nursing women\n9. Patients with contraindications to surgery in general\n10. Patients with an intellectual disability who cannot follow the instructions of their surgeon.","ALL","22 Years",{"count":20,"type":21},163,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to meet a PMA (P240020) condition of approval of the TOUCH® CMC 1 Prosthesis to evaluate the effectiveness and safety of the prosthesis in the United States (US) population. The device performance in newly enrolled US patients implanted by US surgeons will be compared to device performance observed within the outside the US (OUS) premarket cohort.",[25,26],"Osteoarthritis Thumb","Thumb Carpometacarpal Joint Osteoarthritis","RECRUITING","2026-06-02",{"date":30,"type":31},"2026-06-04","ACTUAL",{"date":33,"type":31},"2026-03-04",{"date":35,"type":21},"2030-02",{"name":37,"class":38},"Keri Medical SA","INDUSTRY",4,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100558071","post-market-clinical-follow-up-keriflex-100558071","NCT06546345","Post Market Clinical Follow-Up KeriFlex®","Effectiveness and Safety of the Silicone Joint Implant KeriFlex® and of Its Associated Instruments in the Treatment of MCP and PIP Arthritis: Post Market Clinical Follow up","Inclusion Criteria:\n\n* Adult patients (age ≥ 18 years)\n* Patients who are going to undergo arthroplasty of the metacarpophalangeal or proximal interphalangeal joint using a KeriFlex® implant in accordance with the instructions for use and the labelling in force.\n* Patients with rheumatoid arthritis, osteoarthritis or post-traumatic osteoarthritis\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Patients with an intellectual disability who cannot follow their surgeon's instructions\n* Patients with general surgery contraindications and particularly to the implantation of a KeriFlex® implant\n* Patients with acute or chronic, local or systemic infections\n* Metacarpal or phalanx destruction or poor bone quality preventing adequate fixation\n* Muscle loss, alteration or vascular deficiency in the affected finger\n* Patients with significant physical activity involving treated joint\n* Children, young growing patients with open epiphyses","18 Years",{"count":49,"type":21},86,"The general objective of this study is to assess the performance and safety of the KeriFlex® silicone joint implant and its associated instruments, used in accordance with the labeling and instructions in force.\n\nThe performance and safety of the KeriFlex® joint implant will be established in the short and long term with regard to the life cycle of the implant.",[52,53,54],"Rheumatoid Arthritis","Degenerative Arthritis","Traumatic Arthritis","2025-09-04",{"date":57,"type":31},"2025-09-11",{"date":59,"type":31},"2023-11-14",{"date":61,"type":21},"2035-01",{"name":37,"class":38},3,""]